Career history of David A. Eiznhamer
Former positions of David A. Eiznhamer
Companies | Position | Start | End |
---|---|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Corporate Officer/Principal | 01/01/2002 | 01/05/2003 |
MediChem Life Sciences, Inc.
MediChem Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of DGI Resolution, Inc., MediChem Life Sciences, Inc. provides research and drug discovery services. The company is based in Woodridge, IL. The company was founded in 1987 by Michael T. Flavin. MediChem Life Sciences was acquired by deCODE genetics, Inc. on March 18, 2002 for $52.85 million. | General Counsel | 01/12/1999 | 01/01/2002 |
ADVANCED LIFE SCIENCES HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2003 | - |
Training of David A. Eiznhamer
Loyola University of Chicago | Doctorate Degree |
Statistics
International
United States | 4 |
Iceland | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences Holdings, Inc. BiotechnologyHealth Technology Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel drugs in therapeutic areas of infection, cancer and inflammation. Its product candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-aquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The company was founded by Michael T. Flavin on January 1, 1999 and is headquartered in Woodridge, IL. | Health Technology |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
MediChem Life Sciences, Inc.
MediChem Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of DGI Resolution, Inc., MediChem Life Sciences, Inc. provides research and drug discovery services. The company is based in Woodridge, IL. The company was founded in 1987 by Michael T. Flavin. MediChem Life Sciences was acquired by deCODE genetics, Inc. on March 18, 2002 for $52.85 million. | Commercial Services |
- Stock Market
- Insiders
- David A. Eiznhamer
- Experience